clinical trial · NCT04856930
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa
Hidradenitis SuppurativaImsidolimabPlacebo
brief summary
Efficacy and safety of imsidolimab (ANB019) in participants with Hidradenitis Suppurativa
started
Jul 7, 2021
primary completion
Jul 15, 2022
completion
Dec 14, 2022
last updated
Sep 22, 2025
detailed description
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab in adult participants with hidradenitis suppurativa (HS). This study will also characterize the pharmacokinetic (PK) profile of imsidolimab and explore the immune response to imsidolimab in participants with HS.
official title
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol